25 May 2012 Oryzon nominates specific LSD1 inhibitor as drug candidate to enter preclinical development in Acute leukemia and other hematological cancers
13 June 2012 Oryzon assigns Dr. Xavier Luria as Non-Executive Director of Medical and Regulatory Affairs
10 September 2012 ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia
24 October 2014 ORYZON awarded 1,1 Million EUROS grant to develop its EPIGENETIC LSD1 inhibitors for Acute Leukemia
2 May 2013 Oryzon to Present its LSD1 programs in Acute Leukemias and in Neurodegenerative disorders at the GTC’s 3rd Epigenetics in Drug Discovery conference in Boston
17 May 2013 Oryzon will participate at the 14th International Conference on Alzheimer’s Drug Discovery
15 July 2013 Oryzon obtains orphan designation for ORY-1001 for the treatment of Acute Myeloid Leukemia from the European Medicines Agency